Renal Impairment in Type 2 Diabetic Subjects

Completed · Phase 1

Conditions studied: Diabetes Mellitus, Type 2

In brief

The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with normal renal function

Key facts

Study ID

NCT00554450

Run by

AstraZeneca

People needed

40

Starts

2006-03-01

Expected to finish

2008-10-01

Last updated by the study team

2016-10-17

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.

Where it is running

• Advanced Clinical Research Institute — Anaheim, California, United States
• Elite Research Institute — Miami, Florida, United States
• Prism Research — Saint Paul, Minnesota, United States
• Dgd Research, Inc. — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.